Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | NEJM

Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chr…

Read the full article here

Related Articles